Phase III commencement 1st half CY07. SPA approval likely by FDA in CY07. More Phase II data on other cancer indication due Q1CY07. Big Pharma deal likely CY07. Share price grossly undervalued at present levels (Jan 2007). Analyst (eGCapital) target $19.

Strong volume and a break out in december.
Thanks, nice finding!

Santana, I have been familiar with Progen for years.
Coming home to roost now.
I tipped PGLA in the Fantasyetrader contest in Oct 06.
Still the leading stock for yr. 2.
http://www.fantasyetrader.com/page8.html
PGLA only just starting its long run north.
So much more positive news to come.
www.progen.com.au
Home exchange code PGL.AX

An extract from a long article in BRW about how new technologies will change our lives:


QUOTE
Developments in products and life sciences that will change the way people live and how long they live are on their way. .......

A glimpse of how changes to systems can be disruptive is seen with the internet - a new distribution system that has transformed entire industries and changed the character of the global economy. Something similar can be expected to emerge from the new sciences, disrupting not just specific product markets but entire industry structures.

Not that there is any shortage of dramatic product initiatives. The managing director of biotech venture capital firm eG Capital, Mark Fordree, says changes in cancer treatment, called anti-angiogenesis, will transform the way the disease is approached. "It [Avastin] stops the blood vessels feeding tumours," he says. "Instead of trying to kill the cancer cells, we will just turn them off."

Another Australian product in phase-two trials is Progen, a treatment for liver cancer, he says. "It will take the world by storm. There is no post-operative treatment for liver cancer."
end quote

Thanks D for posting elsewhere

PI-88 Data to be Presented at Key International Conferences

Brisbane, Australia. 12 March 2007: Progen Industries Limited (ASX: PGL; NASDAQ: PGLA) is pleased to announce that its PI-88 Phase II liver cancer data has been accepted for late breaking news presentation by the European Association for the Study of the Liver (EASL).
Progen will also be presenting the results of this liver cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2007.

In expectation of having final data fully analysed and ready for disclosure, Progen is planning for Professor PJ Chen, Principal Investigator of this trial, to present the 48 week data for all 172 patients that were recruited to this multi-site Phase II clinical trial. This presentation will take place on Saturday 14 April 2007 at the 42nd EASL Annual Meeting, which is to be held in Barcelona , Spain from April 11-15, 2007.

Dr. Anand Gautam, Progen’s VP of Discovery Research, will be presenting results at the AACR Annual Meeting 2007, which will be held in Los Angeles , U.S, from April 14-18, 2007.

About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases.

Progen’s three key areas of focus are:

· Clinical Development - via a focused clinical trial program involving its two compounds PI-88 and PI-166.

· Drug Discovery - projects focusing on the development of potent, selective inhibitors of carbohydrate-protein interactions, which are implicated in many disease processes.

· Manufacturing Services – PI-88 manufacturing development and supply for the clinical program and contract manufacturing services.

Keywords - Progen, liver cancer, PI-88.

Other information about Progen:
Half yearly report/half year accounts www.progen.com.au/?page=nepress2007.html

SPP exceeds expectations www.progen.com.au/?page=nepress2007.html

Progen – Notice of General Meeting www.progen.com.au/?page=nepress2007.html

Progen buys back royalty from Medigen www.progen.com.au/?page=nepress2007.html

Capital Raising to Progress PI-88 to Phase 3 www.progen.com.au/?page=nepress2006.html

Preliminary Results for Phase 2 liver cancer trial www.progen.com.au/?page=nepress2006.html

PI-88 mode of action www.progen.com.au/?page=repi-88.html

Progen’s drug development pipeline www.progen.com.au/?page=pihome.html

Progen Industries Ltd www.progen.com.au